# US 5,707,629 A · Immunogenic composition against equine herpesvirus type 1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,707,629 A
- Document ID: US5707629A
- Status: Granted
- Kind: A
- Application number: 08/341,781
- Filed: 1994-11-18
- Granted: 1998-01-13
- Earliest claimed: 1990-08-01
- Assignees: Research Corporation Technologies, Inc.
- Inventors: Dennis J. O'Callaghan
- Web page: https://patentgrep.com/patent/US5707629A

## CPC

- C07K 14/005: from viruses
- C07K 16/087: Herpes simplex virus
- C12N 15/86: Viral vectors
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C12N 2710/14143: viral genome or elements thereof as genetic vector
- C12N 2710/16722: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is directed to a gene encoding an envelope glycoprotein of equine herpesvirus type 1 (EHV-1), the glycoprotein D (gD) gene, its gene product and antibodies directed against gD polypeptides. The envelope glycoproteins of herpesvirus are major targets of the immune response to herpesviral infection. Hence, an important aspect of this invention is directed towards a vaccine against EHV-1 and treatment of EHV-1 infection by anti-EHV-gD antibodies or antisera.

## Claims

### Claim 1

An isolated peptide comprising a portion of the sequence of Equine Herpes Virus-1 gD, wherein the portion comprises the sequence of amino acids 80-98 of FIG. 2.

### Claim 2

An isolated peptide comprising a portion of the sequence of Equine Herpes Virus-1 gD, wherein the portion comprises the sequence of amino acids 343-362 of FIG. 2.

### Claim 3

An isolated polypeptide comprising amino acids 1-442 of the Equine Herpes Virus-1 gD polypeptide of FIG. 2.

### Claim 4

An isolated polypeptide comprising amino acids 51-442 of the Equine Herpes Virus-1 gD polypeptide of FIG. 2.

### Claim 5

An isolated polypeptide comprising amino acids 57-442 of the Equine Herpes Virus-1 gD polypeptide of FIG. 2.

### Claim 6

An isolated polypeptide comprising amino acids 58-442 of the Equine Herpes Virus-1 gD polypeptide of FIG. 2.

### Claim 7

An isolated polypeptide comprising amino acids 77-442 of the Equine Herpes Virus-1 gD polypeptide of FIG. 2.

### Claim 8 (depends on 1)

An immunogenic composition comprising the peptide of claim 1 and a pharmaceutically acceptable carrier.

### Claim 9 (depends on 2)

An immunogenic composition comprising the peptide of claim 2 and a pharmaceutically acceptable carrier.

### Claim 10 (depends on 3)

An immunogenic composition comprising the polypeptide of claim 3 and a pharmaceutically acceptable carrier.

### Claim 11 (depends on 4)

An immunogenic composition comprising the polypeptide of claim 4 and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 5)

An immunogenic composition comprising the polypeptide of claim 5 and a pharmaceutically acceptable carrier.

### Claim 13 (depends on 6)

An immunogenic composition comprising the polypeptide of claim 6 and a pharmaceutically acceptable carrier.

### Claim 14 (depends on 7)

An immunogenic composition comprising the polypeptide of claim 7 and a pharmaceutically acceptable carrier.